Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-022902
Filing Date
2022-11-08
Accepted
2022-11-08 07:21:37
Documents
77
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q cere-20220930.htm   iXBRL 10-Q 4069308
2 EX-31.1 cere-ex31_1.htm EX-31.1 19584
3 EX-31.2 cere-ex31_2.htm EX-31.2 19570
4 EX-32.1 cere-ex32_1.htm EX-32.1 11236
5 EX-32.2 cere-ex32_2.htm EX-32.2 11242
6 GRAPHIC img32109788_0.jpg GRAPHIC 81988
  Complete submission text file 0000950170-22-022902.txt   13126201

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cere-20220930_cal.xml EX-101.CAL 59042
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cere-20220930_pre.xml EX-101.PRE 371489
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cere-20220930.xsd EX-101.SCH 59249
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cere-20220930_def.xml EX-101.DEF 223779
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cere-20220930_lab.xml EX-101.LAB 487390
71 EXTRACTED XBRL INSTANCE DOCUMENT cere-20220930_htm.xml XML 2745207
Mailing Address 222 JACOBS STREET SUITE 200 CAMBRIDGE MA 02141
Business Address 222 JACOBS STREET SUITE 200 CAMBRIDGE MA 02141 844-304-2048
Cerevel Therapeutics Holdings, Inc. (Filer) CIK: 0001805387 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39311 | Film No.: 221367214
SIC: 2834 Pharmaceutical Preparations